Cargando…
i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations
Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new precise personalized strategy named "i-CRISPR" for cancer treatment through adding DN...
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380384/ https://www.ncbi.nlm.nih.gov/pubmed/35974394 http://dx.doi.org/10.1186/s12943-022-01612-x |
| _version_ | 1784768875202609152 |
|---|---|
| author | Jiang, Junfeng Chen, Yuanyuan Zhang, Li Jin, Qishu Wang, Liujun Xu, Sha Chen, Kexin Li, Li Zeng, Tao Fan, Xingfei Liu, Tingting Li, Jiaxi Wang, Jinjiang Han, Chaofeng Gao, Fu Yang, Yanyong Wang, Yue |
| author_facet | Jiang, Junfeng Chen, Yuanyuan Zhang, Li Jin, Qishu Wang, Liujun Xu, Sha Chen, Kexin Li, Li Zeng, Tao Fan, Xingfei Liu, Tingting Li, Jiaxi Wang, Jinjiang Han, Chaofeng Gao, Fu Yang, Yanyong Wang, Yue |
| author_sort | Jiang, Junfeng |
| collection | PubMed |
| description | Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new precise personalized strategy named "i-CRISPR" for cancer treatment through adding DNA damage repair inhibitors(i) and inducing cancer cell-specific DNA double strand breaks by CRISPR. Through in vitro and in vivo experiments, we confirmed the efficacy of this strategy in multiple cancer models and revealed the mechanism of cell death. Our strategy might provide a novel concept for precise cancer therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01612-x. |
| format | Online Article Text |
| id | pubmed-9380384 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93803842022-08-17 i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations Jiang, Junfeng Chen, Yuanyuan Zhang, Li Jin, Qishu Wang, Liujun Xu, Sha Chen, Kexin Li, Li Zeng, Tao Fan, Xingfei Liu, Tingting Li, Jiaxi Wang, Jinjiang Han, Chaofeng Gao, Fu Yang, Yanyong Wang, Yue Mol Cancer Letter to the Editor Developing a strategy to specifically kill cancer cells without inducing obvious damage to normal cells may be of great clinical significance for cancer treatment. In the present study, we developed a new precise personalized strategy named "i-CRISPR" for cancer treatment through adding DNA damage repair inhibitors(i) and inducing cancer cell-specific DNA double strand breaks by CRISPR. Through in vitro and in vivo experiments, we confirmed the efficacy of this strategy in multiple cancer models and revealed the mechanism of cell death. Our strategy might provide a novel concept for precise cancer therapy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12943-022-01612-x. BioMed Central 2022-08-16 /pmc/articles/PMC9380384/ /pubmed/35974394 http://dx.doi.org/10.1186/s12943-022-01612-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Letter to the Editor Jiang, Junfeng Chen, Yuanyuan Zhang, Li Jin, Qishu Wang, Liujun Xu, Sha Chen, Kexin Li, Li Zeng, Tao Fan, Xingfei Liu, Tingting Li, Jiaxi Wang, Jinjiang Han, Chaofeng Gao, Fu Yang, Yanyong Wang, Yue i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title | i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title_full | i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title_fullStr | i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title_full_unstemmed | i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title_short | i-CRISPR: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| title_sort | i-crispr: a personalized cancer therapy strategy through cutting cancer-specific mutations |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9380384/ https://www.ncbi.nlm.nih.gov/pubmed/35974394 http://dx.doi.org/10.1186/s12943-022-01612-x |
| work_keys_str_mv | AT jiangjunfeng icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT chenyuanyuan icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT zhangli icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT jinqishu icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT wangliujun icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT xusha icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT chenkexin icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT lili icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT zengtao icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT fanxingfei icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT liutingting icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT lijiaxi icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT wangjinjiang icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT hanchaofeng icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT gaofu icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT yangyanyong icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations AT wangyue icrisprapersonalizedcancertherapystrategythroughcuttingcancerspecificmutations |